Mesobllast ltd. (MESO) the stock was flying as high as 10.12% in the post-market session on December 1, 2020, even after it was reported that Frank R. Cruz’s Law Office advises clients that class action cases have been brought on behalf of the owners of the following publicly listed firms. Investors have until the time limits set out below to file a lawsuit with the lead plaintiff.

Investors experiencing damages in their assets are urged to contact the Frank R. Cruz Law Office to discuss their civil interests in these class cases at 310-914-5007 or via e-mail fcruz@frankcruzlaw.com.

Mesobllast Minimal (NASDAQ: MESO)

Class Period: April 16, 2019 – October 1, 2020.

Lead Plaintiff Deadline: December 7, 2020

The lawsuit alleges that during the Class Period, the Defenders made materially inaccurate and misleading claims and refused to reveal significant adverse information regarding the Company’s market, activities and prospects. Specifically, the Defenders refused to report to investors:

(1) that the comparative review between the Phase 3 trial of Mesoblast and the three historical trials did not confirm the efficacy of remestemcel-L in steroid refractory aGVHD due to variations in nature between the four studies;

(2) that as a result, the FDA was fairly likely to require more clinical studies;

(3) that as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) that as a result of the above, the optimistic comments of the Defenders on the Company’s market, operations, and prospects were materially deceptive and/or lack of a fair basis.